research

Rimonabant improves cardiometabolic risk factors in overweight/obese patients with poorly controlled type 2 diabetes (HbA(1c)>= 8%) on monotherapy with metformin or sulfonylureas

Authors
Publication date
1 September 2006
Publisher
'Springer Fachmedien Wiesbaden GmbH'

Abstract

peer reviewe

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Open Repository and Bibliography - Liège

    redirect
    oaioai:orbi.ulg.ac.be:2268/7169
    Last time updated on 20/08/2013